Amgen

(Image: Getty/LightFieldStudios)

Amgen joins neuroscience exodus

By Ben Hargreaves

In third quarter financials, Amgen announces that it will end its R&D efforts in neuroscience to focus on diseases with a ‘large public health impact.

(Image: Getty/Tetiana Lazunova)

Pharma takes interest in genomics to next level

By Ben Hargreaves

Four pharma companies are providing half of the investment required for ‘world’s largest genetics project’, in return for access to the genomic data generated.

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers